# Leveraging systems pharmacology to advance precision medicine for Gabapentin treatment of AUD

> **NIH NIH R01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $760,789

## Abstract

Project Summary / Abstract
The overall goal of this proposal is to leverage systems pharmacology to advance precision medicine for
gabapentin treatment of AUD. The current proposal will utilize DNA and RNA samples available from a completed
NIAAA sponsored study on Gabapentin Enacarbil Extended – Release (GE-XR) for AUD and resources from
our NYU Center for PrecisionMedicine in Alcohol Use Disorder and PTSD. Our Center was created in September
2018 with funding from an NIAAA P01 “Leveraging biomarkers for personalized treatment of alcohol use disorder
comorbid with PTSD”. Our NYU Center focuses on advancing precision medicine for alcohol use disorders,
including those comorbid with PTSD, utilizing molecular and circuit markers and advanced computational models
for determining responders and non-responders to treatment. The primary aims focused to advance precision
medicine by discovering pharmagenomic, pharmacoepigenomic and pharmacotranscriptomic predictors of
individual differences in responses to GE-XR treatment of AUD. There will be eight pathways to be prioritized as
part of the primary aims of the proposal. The pathways are: voltage sensitive channels, excitatory and inhibitory
amino acids, gabapentin amino acid transporters, serotonin pathway, rewarding properties of alcohol, neuor-
inflammatory, apoptotic/oxidative stress and neurotrophic factors. The secondary aim focuses on discovering
novel targets and pathways. The group will utilize polymorphisms, epigenetic marks, transcripts and miRNA
markers for discovery of novel targets and pathways for predicting individual responses in alcohol use in
participants. The data to be ascertained from the proposed aims have potential for discovery of novel genomic
features to predict responders and non-responders for GE-XR treatment of AUC. These discoveries would
significantly contribute to the NIAAA goal of advancing precision medicine within the domain of AUC. More
broadly, the novel computational methods that we will advance in this proposal for modelling genomic predictors
of likely responders hold promise for advancing precision medicine for other medications for AUD and for
personalized treatments of other substance use disorders.

## Key facts

- **NIH application ID:** 10421522
- **Project number:** 1R01AA030036-01
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Charles R Marmar
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $760,789
- **Award type:** 1
- **Project period:** 2022-06-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10421522

## Citation

> US National Institutes of Health, RePORTER application 10421522, Leveraging systems pharmacology to advance precision medicine for Gabapentin treatment of AUD (1R01AA030036-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10421522. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*